Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

InMed Pharmaceuticals — 14 videos in collection

More on this equity

In this video, InMed CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to reduce intraocular pressure and neuroprotection of the eye, important for glaucoma and several other eye diseases. InMed has conducted a number of preclinical studies of CBN, comparing it against several cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBN clearly demonstrated the most optimal effect for glaucoma over other cannabinoids.

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free